Study Summary
This is a single arm study to evaluate the efficacy and safety of CD123-targeted CAR-T cells therapy for patients with relapsed/refractory Acute Myeloid Leukemia.
Interested in this trial?
Submit an InquiryInterventions
CD123 CAR-T cellsBIOLOGICAL
A single infusion of CD123-CAR-T cells will be administered intravenously
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Chongqing University Cancer Hospital | Chongqing | Chongqing Municipality | China |